

Ref: Syn/CS/SE/Reg 30/2020-21/Aug/51

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area,
IV Phase, Jigani Link Road,
Bengaluru 560 099, Karnataka, India
T +91 80 6891 8000
CIN: L85110KA1993PLC01493
www.syngeneintl.com

August 20, 2020

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 – Impact of Covid-19 pandemic.

Please find enclosed the disclosure on the impact of COVID-19 pandemic on the Company as required under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 (enclosed herewith as “Annexure I”).

The above information will also be available on the website of the Company at www.syngeneintl.com.

We request you to kindly take this information on record and oblige.

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary & Compliance Officer

S. No.	Particulars	Disclosures
1.	Impact of the COVID-19 on the business.	The Company invoked its business continuity plan during the initial phase of the nation-wide lockdown and rapidly implemented measures to ensure the safety and wellbeing of employees while protecting the sites and critical operations. Syngene believes it has taken appropriate measures to safeguard its operations in light of the COVID-19 pandemic and is currently operating at close to 100% of normal operations.
2.	Ability to maintain operations including the factories/ units/ office spaces functioning and closed down.	After the temporary suspension of operations during the initial nation-wide lockdown, the Company swiftly made adjustments to the facilities and working practices, which helped in resuming operations relatively quickly. Pharmaceutical and research companies being categorised as essential services, the Company was allowed to continue to operate during the lockdown. From the very early stages of the pandemic, Syngene put together a cross functional COVID-19 response team to continuously monitor the situation and take necessary and prompt actions.
3.	Schedule, if any, for restarting the operations.	Refer to Point 2 above
4.	Steps taken to ensure smooth functioning of operations.	Over the last few months, a series of safety measures have been implemented across various facilities aimed at making the work place safe and keeping employees healthy. These include zoning across the campuses to restrict movement, introduce physical distancing in common areas like cafeteria, company transport bus, elevators, temperature check of all individuals entering the campus using handheld infrared thermometers and enhanced housekeeping and sanitation. Employees whose work profile enables them to operate remotely have been permitted to work from home and the IT infrastructure is fully geared to support onsite as well as remote working in a secure environment. A proactive communication campaign was initiated to educate employees on following good hygiene practices and keeping them updated about government guidelines. The Company has since been operating at nearly normal levels and has brought most of its projects back on schedule.
5.	Estimation of the future impact of COVID-19 on our operations.	The pandemic creates a degree of uncertainty for the months ahead due to the impact on the global economy in the long-term. The Company continues to assess the situation on an ongoing basis and is closely monitoring the impact of the same on employee safety, business operations, financial performance, customers, vendors and business partners. The supply chain function has been continuously monitoring the supply scenario for various raw materials and other items to ascertain any potential delays and take necessary actions

		including tying up with alternate vendors. Syngene is also focused on adapting its approach to sales and marketing and client engagement through the use of digital technologies and channels. However, these approaches being in the nascent stage, the Company is yet to evaluate their effectiveness in driving future sales performance.
6.	Impact of COVID-19 on:	
	• Capital and financial resources	None
	• Profitability	Not Material
	• Liquidity position	None
	• Ability to service debt and financing arrangements	None. Recently the rating agencies, CRISIL and ICRA have upgraded Syngene's Long-Term Issuer Rating to 'AA+' from 'AA'.
	• Assets	The Company has assessed the impact of COVID-19 as on 31 st March, 2020 and it is expected to fully recover the carrying amount of trade-receivables, unbilled revenues, investments and other assets. However, the actual impact of COVID-19 on the various assets may differ from that estimated.
	• Internal financial reporting and control,	All internal controls and financial reporting systems continue to be fully operational.
	• Supply chain and	The Company is honouring all delivery commitments with customers and financial commitments with respect to Vendors and partners and accordingly there is no material impact on the supply chain/ delivery.
	• Demand for its products/ services	Not Material
7.	Existing contracts/ agreements where non-fulfilment of the obligations by any party will have significant impact on the listed entity's business.	No significant impact of such non- fulfilment of the obligations by any party on the business is expected.
8.	Other relevant material updates about the listed entity's business.	None. The Company will provide an update as and when there is any material impact on business.